Safety and efficacy of tenofovir/IQP-0528 combination gels – A dual compartment microbicide for HIV-1 prevention

► Tenofovir/IQP-0528 microbicide combination gels were tested for safety and efficacy. ► Polarized ectocervical and colorectal tissues were used to evaluate these gels. ► Combination gels were safe toward mucosal tissue and blocked HIV infection. ► These gels provide the foundation of a dual compart...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antiviral research 2012-11, Vol.96 (2), p.221-225
Hauptverfasser: Dezzutti, Charlene S., Shetler, Cory, Mahalingam, Alamelu, Ugaonkar, Shweta R., Gwozdz, Garry, Buckheit, Karen W., Buckheit, Robert W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:► Tenofovir/IQP-0528 microbicide combination gels were tested for safety and efficacy. ► Polarized ectocervical and colorectal tissues were used to evaluate these gels. ► Combination gels were safe toward mucosal tissue and blocked HIV infection. ► These gels provide the foundation of a dual compartment, combination product microbicide. Tenofovir (TFV) is a nucleotide reverse transcriptase inhibitor and IQP-0528 is a non-nucleoside reverse transcriptase inhibitor that also blocks virus entry. TFV and IQP-0528 alone have shown antiviral activity as microbicide gels. Because combination therapy will likely be more potent than mono-therapy, these drugs have been chosen to make a combination microbicide gel containing 2.5% TFV/1% IQP-0528. Safety and efficacy testing was done to evaluate five prototype combination gels. The gels retained TZM-bl cell and ectocervical and colorectal tissue viability. Further, the epithelium of the ectocervical and colorectal tissue remained intact after a 24h exposure. The ED50 calculated from the formulations for IQP-0528 was ∼32nM and for TFV was ∼59nM and their inhibitory activity was not affected by semen. The ED50 of TFV in the combination gels was ∼100-fold lower than when calculated for the drug substance alone reflecting the activity of the more potent IQP-0528. When ectocervical and colorectal tissue were treated with the combination gels, HIV-1 p24 release was reduced by ⩾1log10 and ⩾2log10, respectively. Immunohistochemistry for the ectocervical tissues treated with combination gels showed no HIV-1 infected cells at study end. With the increased realization of receptive anal intercourse among heterosexual couples often in conjunction with vaginal intercourse, having a safe and effective microbicide for both mucosal sites is critical. The safety and efficacy profiles of the gels were similar for ectocervical and colorectal tissues suggesting these gels have the potential for dual compartment use.
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2012.08.004